JOINT ACTION 3

Home  /  JOINT ACTION 3 (Page 3)

EUnetHTA deems patient involvement very important in the production of Joint/Collaborative Assessment reports. We recognise that patients and those who support them have unique knowledge about what it is like to live with a specific disease or medical condition. We

This is the pharmaceutical Joint Assessment PTJA09 on brolucizumab. In February 2020, the European Commission granted marketing authorisation for Beovu® (brolucizumab) for the treatment of adults with neovascular (wet) AMD. This Joint Assessment aims to compare the clinical effectiveness and

This is the pharmaceutical Joint Assessment PTJA08 – on siponimod for the treatment of active SPMS. In January 2020, the European Commission granted marketing authorisation for Mayzent® (siponimod) for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS)